In two syngeneic models of melanoma and renal cell carcinoma, rIL-21 given intratumorally strongly inhibited tumor growth and increased the frequency of tumor-infiltrating CD8+ T cells and mice survival [110]. This evidence concerns the gene CD8A and neoplasm.